Angiodynamics Inc income statement

In fiscal 2026, Angiodynamics Inc reported revenue of $320m, up 9.5% on the year before, operating income of −$39.9m (a -12.5% margin) and net income of −$36.7m, or −$0.88 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Angiodynamics Inc: income statement, annual
Fiscal year	2010May 2010	2011May 2011	2012May 2012	2013May 2013	2014May 2014	2015May 2015	2016May 2016	2017May 2017	2018May 2018	2019May 2019	2020May 2020	2021May 2021	2022May 2022	2023May 2023	2024May 2024	2025May 2025	2026May 2026	LTMAug 2026
Revenue	216	216	222	342	354	357	354	270	262	271	264	291	316	339	304	292	320	325
Cost of revenue	—	—	—	—	—	—	180	126	118	115	114	134	150	165	149	135	145	144
Gross profit	127	126	125	169	180	176	174	144	144	156	150	157	166	174	155	158	175	181
Research and development	19	21	21	26	28	27	25	24	24	28	30	36	31	30	32	26	29	31
Selling and marketing	61	58	66	78	85	82	84	75	73	77	79	81	95	104	103	103	113	115
General and administrative	16	18	19	26	27	30	31	31	31	35	38	36	38	40	41	42	44	44
Operating income	21	12	−5	5	10	−3	1	−11	−14	−9	−167	−35	−28	−51	−192	−40	−40	−37
Interest expense	1	0	1	5	4	3	3	3	3	5	1	1	1	3	−2	—	—	—
Income before tax	20	11	−6	−1	5	−8	−3	−14	−17	−15	−168	−36	−30	−54	−192	−34	−36	−33
Income tax	7	3	−0	−0	−9	−5	40	−7	−11	−4	−1	−5	−3	−2	−7	−0	0	0
Net income	12	8	−5	−1	2	−3	−44	5	16	61	−167	−32	−27	−52	−184	−34	−37	−33
Diluted EPS	$0.50	$0.32	−$0.20	−$0.03	$0.07	−$0.09	−$1.21	$0.14	$0.44	$1.64	−$4.39	−$0.82	−$0.68	−$1.33	−$4.59	−$0.83	−$0.88	−$0.79
Diluted shares (average)	25m	25m	25m	35m	35m	36m	36m	37m	37m	37m	38m	38m	39m	39m	40m	41m	42m	42m
EBITDA	33	24	9	32	39	26	29	14	9	16	−143	−9	1	−20	−165	−14	−17	−14

US$ millions unless shown otherwise. Fiscal quarters.

Angiodynamics Inc: income statement, quarterly
Quarter	2025 Q2Nov 2024	2025 Q3Feb 2025	2025 Q4May 2025	2026 Q1Aug 2025	2026 Q2Nov 2025	2026 Q3Feb 2026	2026 Q4May 2026	2027 Q1Aug 2026
Revenue	73	72	80	76	79	78	87	81
Cost of revenue	33	33	38	34	35	37	40	33
Gross profit	40	39	42	42	45	41	47	48
Research and development	6	7	7	6	8	7	8	8
Selling and marketing	26	26	26	28	27	27	31	30
General and administrative	10	10	10	13	10	11	10	12
Operating income	−11	−10	−6	−11	−6	−13	−10	−7
Income before tax	−11	−4	−6	−11	−6	−8	−11	−7
Income tax	−0	−0	−0	0	−0	0	0	−0
Net income	−11	−4	−6	−11	−6	−8	−11	−7
Diluted EPS	−$0.26	−$0.11	−$0.15	−$0.26	−$0.15	−$0.19	−$0.27	−$0.17
EBITDA	−4	−4	0	−5	−0	−7	−5	−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANGO vs PRCT ANGO vs STAA ANGO vs INGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Angiodynamics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Angiodynamics Inc.